Adhera Therapeutics Inc (ATRX) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 3.73: the stock has moved about 273% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAdhera Therapeutics Inc (ATRX) trades at $0.0001. Adhera Therapeutics, Inc. is a biotechnology company focused on the discovery and development of drugs. Formerly known as Marina Biotech, the company is based in Baton Rouge, Louisiana. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for ATRX: ATRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Adhera Therapeutics Inc (ATRX) Healthcare & Pipeline Overview
Adhera Therapeutics, Inc., formerly Marina Biotech, focuses on drug discovery and development within the biotechnology sector. Based in Baton Rouge, Louisiana, the company operates with a small team, navigating the competitive landscape of pharmaceutical innovation with a focus on identifying and advancing novel therapeutic candidates.
What Is the Investment Thesis for ATRX?
Investing in Adhera Therapeutics presents a high-risk, high-reward scenario typical of early-stage biotechnology companies. With a market capitalization of $0.00 billion and a negative price-to-earnings ratio, the company's valuation is speculative and tied to the potential success of its drug development pipeline. A key value driver is the advancement of drug candidates through clinical trials, which could trigger significant stock appreciation. Upcoming catalysts include potential partnerships, grant funding, and positive clinical trial results. However, the company faces substantial risks, including limited financial resources, regulatory hurdles, and competition from larger pharmaceutical companies. The high beta of 3.73 indicates significant volatility, making this investment suitable only for risk-tolerant investors.
Based on FMP financials and quantitative analysis
ATRX Key Highlights
Market capitalization of $0.00 billion, reflecting its status as a micro-cap company.
- Negative price-to-earnings ratio, indicating the company is currently not profitable.
- Beta of 3.73, suggesting high volatility compared to the overall market.
- Focus on drug discovery and development, positioning it within the high-growth biotechnology sector.
- Operates with a small team of 2 employees, indicating a lean operational structure.
Who Are ATRX's Competitors?
ATRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.65 | +0.06% | $88.5M | 82 5-pillar |
| ICCC ImmuCell Corporation | $10.24 | -0.10% | $93.6M | 78 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.08 | -1.21% | $170M | 75 5-pillar |
| NAGE Niagen Bioscience Inc | $2.44 | +0.41% | $190M | 70 5-pillar |
| QTTB Q32 Bio Inc. | $8.45 | -2.31% | $252M | 67 5-pillar |
| CLYM Climb Bio, Inc. | $8.81 | -13.54% | $506M | 67 5-pillar |
| ZVRA Zevra Therapeutics, Inc. | $9.53 | -2.85% | $566M | 91 5-pillar |
| MDXG MiMedx Group, Inc. | $3.85 | -1.53% | $570M | 88 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ATRX's Key Strengths?
Focus on drug discovery and development
- Small, agile team
- Potential for breakthrough therapies
- Strategic location in Baton Rouge, Louisiana
What Are ATRX's Weaknesses?
Limited financial resources
- Small team size
- Dependence on external funding
- Lack of commercialized products
What Are the Key Risks for ATRX?
Inconsistent delivery — missed Wall Street EPS estimates in 8 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Limited financial resources to fund drug development programs.
- Competition from larger, better-funded pharmaceutical companies.
- Regulatory hurdles and approval delays for drug candidates.
- Clinical trial failures and setbacks.
- Dependence on external funding and strategic partnerships.
What Are ATRX's Competitive Advantages?
- Proprietary drug discovery platform.
- Intellectual property protection for its drug candidates.
- Expertise in specific therapeutic areas.
What Does ATRX Do?
Adhera Therapeutics, Inc., headquartered in Baton Rouge, Louisiana, is a biotechnology company engaged in the discovery and development of pharmaceutical products. Originally established as Marina Biotech, Inc., the company underwent a name change in October 2018 to reflect its evolving strategic direction. Adhera Therapeutics operates with a lean structure, currently managing its research and development efforts with a team of two employees. The company's primary focus is on identifying and developing novel drug candidates, aiming to address unmet medical needs. While specific details on their current pipeline are not available, the company's history suggests an interest in innovative therapeutic approaches. Adhera Therapeutics navigates the competitive biotechnology landscape, seeking to advance its drug development programs through preclinical and clinical stages.
What Products and Services Does ATRX Offer?
- Focuses on the discovery of new drugs.
- Engages in the development of pharmaceutical products.
- Aims to address unmet medical needs through innovative therapies.
- Conducts preclinical research to identify promising drug candidates.
- Potentially conducts clinical trials to evaluate the safety and efficacy of drug candidates.
- Seeks partnerships and collaborations to advance its drug development programs.
How Does ATRX Make Money?
- Focuses on discovering and developing drugs.
- Seeks to monetize its drug candidates through partnerships or acquisitions.
- May generate revenue through licensing agreements or milestone payments.
What Industry Does ATRX Operate In?
Adhera Therapeutics operates within the highly competitive biotechnology industry, characterized by intense research and development, stringent regulatory requirements, and high capital demands. The industry is driven by innovation, with companies constantly seeking to develop novel therapies for unmet medical needs. The competitive landscape includes established pharmaceutical giants, as well as numerous smaller biotechnology firms. Adhera Therapeutics, with its small size and focus on drug discovery, faces the challenge of competing with larger, better-funded companies. Success in this industry requires strong intellectual property, efficient clinical trial execution, and strategic partnerships.
Who Are ATRX's Key Customers?
- Pharmaceutical companies seeking to expand their drug pipelines.
- Patients who may benefit from new therapies developed by the company.
- Healthcare providers who may prescribe the company's drugs.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Adhera Therapeutics Inc's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Adhera Therapeutics Inc stands at 8.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Adhera Therapeutics Inc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Baton Rouge, US. ATRX has traded publicly since 1993.
Earnings Track Record
Adhera Therapeutics Inc has missed Wall Street's EPS estimate in 8 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 188.7% below estimates on average.
ATRX Financials
ATRX Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
ATRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ATRX.
Price Targets
Wall Street price target analysis for ATRX.
ATRX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ATRX; grades run from A+ (80-100) to F (below 30).
Leadership: Andrew Albert Kucharchuk
CEO
Andrew Albert Kucharchuk serves as the CEO of Adhera Therapeutics, Inc. As the managing member of a small team, Kucharchuk is responsible for overseeing the company's strategic direction and day-to-day operations. His leadership is critical to navigating the challenges of drug discovery and development within the biotechnology sector.
Track Record: Given the limited information available, it is difficult to assess Andrew Albert Kucharchuk's track record at Adhera Therapeutics. The company's small size and early stage of development suggest that Kucharchuk's primary focus has been on securing funding, advancing drug candidates, and building strategic partnerships. Key milestones under his leadership would include successful preclinical studies, IND filings, and positive clinical trial results.
ATRX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Adhera Therapeutics may not meet the minimum financial standards or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier often have limited trading volume and may not be required to provide regular financial reports. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight. This contrasts sharply with companies listed on major exchanges like the NYSE or NASDAQ, which have stringent listing requirements and reporting obligations.
- OTC Tier: OTC Other
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or mismanagement
- Lack of regulatory oversight
- Verify the company's financial statements (if available)
- Research the background of the company's management team
- Assess the company's business model and competitive landscape
- Review any available news articles or press releases
- Consult with a financial advisor
- Understand the risks associated with investing in OTC stocks
- Confirm the company's registration status with the SEC (if applicable)
- Company's history of operations (formerly Marina Biotech)
- Focus on drug discovery and development
- Presence of a CEO and management team
- Company filings with OTC Markets (if available)
- Any patents or intellectual property owned by the company
What Investors Ask About Adhera Therapeutics Inc (ATRX) — Healthcare
What do analysts say about ATRX stock?
As of 2026-03-17, there is no available analyst coverage for Adhera Therapeutics (ATRX). Given its micro-cap status, OTC listing, and limited financial disclosure, the stock is not widely followed by analysts.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on the company's current pipeline and financial performance.
- OTC listing indicates higher risk and lower transparency.